Drug development news
Australian company Clinuvel have announced that their treatment known as SCENESSE® (Afamelanotide, 16mg) was approved as a treatment for the debilitating genetic disorder Erythropoietic Protoporphyria (EPP) in Europe. EPP is characterised by an extreme risk of severe burns (phototoxicity) of the skin. Many EPP sufferers can only venture out at night and can even suffer burns and scarring from bright light.
- Scenesse was also tried in clinical trials for vitiligo. Profs. Henry Lim, Mark Lebwohl and coauthors reported ( PubMed) results of multicenter Phase I clinical trials of Afamelanotide in combination with narrowband UVB. Authors noticed faster and better repigmentation in experimental group compared to the control group receiving only NB-UVB, yet this effect was limited to dark skin types (type IV-VI) but not for type III skin or lighter.
The new drug acts as an anti-oxidant and activates melanin in skin, which in turn increases pigmentation of the skin and provides barrier from harmful UV rays. The benefits are a decrease in light sensitivity, and a limited increase in time EPP patients may spend in daylight. The most common side effects are headache, nausea, nasopharyngitis, migraine, abdominal pain, fatigue, lethargy and somnolence.
Each 16mg implant costs around $6,200 and lasts 60 days.
Under current EMA approval, Scenesse will be closely monitored under a “pharmacovigilance” plan to ensure the treatment remains effective and there is no off-label usage. Despite not being currently approved for vitiligo, this drug may also be one of the treatment options for some vitiligo sufferers down the road.
I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.
What is coming?
XXIII Master Class in Cuba
will be held as a part of INDERCOS Winter Meeting, in collaboration with Cuban Vitiligo Support and Research Group. International and national expert speakers will di...16 November 2017 09:00, Hotel Nacional de Cuba, Habana, Cuba
High-level Meeting on the Asian and Pacific Decade of People With Disabilities
The UN's Economic and Social Commission for Asia and the Pacific (ESCAP), in cooperation with the China Disabled Persons’ Federation (CDPF), is organizing the High-lev...27 November 2017 09:00, Beijing, China
What tests should be done?
No tests are usually necessary to make the diagnosis. The white patches may be seen more easily under Wood's light examination.
I have vitiligo: will my children have vitiligo, too?
In some cases vitiligo seems to be inherited and run in families, with children whose parents have vitiligo being at increased risk of developing the condition themsel...
What causes vitiligo?
The precise cause of vitiligo is not well understood. The white areas appear due to loss of the pigment (melanin) that gives skin its color and protects it from the su...
Dermaroller® use for vitiligo therapy
A derma-roller is a medical device that looks like a cylindrical shaped drum studded with very fine needles and is produced under several different names. It is used i...